MiNK Therapeutics
INKT
24 hedge funds and large institutions have $632K invested in MiNK Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0.04% less ownership
Funds ownership: 0.26% → 0.21% (-0.04%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
17% less funds holding
Funds holding: 29 → 24 (-5)
25% less capital invested
Capital invested by funds: $848K → $632K (-$215K)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
+$10.1K |
| 2 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
+$9.17K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.54K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.38K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$882 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$17.9K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$17.3K |
| 3 |
Goldman Sachs
New York
|
-$16.7K |
| 4 |
Millennium Management
New York
|
-$12.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JIP
26
Jaffetilchin Investment Partners
Tampa,
Florida
| $1 | – | – | – |
|
|
27
Goldman Sachs
New York
| – | -$16.7K | -1,756 | Closed |
|
|
28
Millennium Management
New York
| – | -$12.5K | -1,312 | Closed |
|
29
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$1.84K | -194 | Closed |
|
30
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| – | -$1.47K | -155 | Closed |
|
|
CP
31
Camelot Portfolios
Maumee,
Ohio
| – | -$195 | -21 | Closed |
|
|
HIA
32
Harbor Investment Advisory
Lutherville,
Maryland
| – | -$5 | -1 | Closed |
|
33
AssetMark Inc
Concord,
California
| – | -$1 | – | – |
|
INKT Hedge Fund Activity: Q3 2024 in Review
24 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q3 2024, worth a combined $632K — down 25% from $848K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of INKT and 2 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $10.1K. The largest seller was Renaissance Technologies, cutting an estimated $17.9K.
- 24 institutional investors held MiNK Therapeutics (INKT) as of Q3 2024, down from 29 in Q2 2024.
- Funds reported $632K of MiNK Therapeutics stock for Q3 2024, down 25% quarter-over-quarter.
- 2 funds opened new MiNK Therapeutics positions in Q3 2024 and 7 closed out, a net change of -5 holders.
- The largest MiNK Therapeutics buyer in Q3 2024 was Two Sigma Securities, an estimated $10.1K added.
- The largest MiNK Therapeutics seller in Q3 2024 was Renaissance Technologies, an estimated $17.9K sold.
Based on aggregated 13F filings for Q3 2024.